Clinical trial · Observational
Analysis of miRNA Expression in Endometrial Cancer
Identification of miRNAs in Endometrial Cancer as Novel Diagnostic and Prognostic Biomarkers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The TCGA project identified four distinct prognostic groups of endometrial carcinoma (EC) based on molecular alterations: (i) the ultramutated subtype that encompasses POLE mutated (POLE) cases; (ii) the hypermutated subtype, characterized by MisMatch Repair deficiency (MMRd); (iii) the copy-number high subtype, with p53 abnormal/mutated features (p53abn); (iv) the copy-number low subtype, known as No Specific Molecular Profile (NSMP). Although the prognostic value of TCGA molecular classification, NSMP carcinomas present a wide variability in molecular alterations and biological aggressiveness. Given that the study aims to evaluate the miRNA expression profile to identify novel potential biomarkers to better stratify the EC patients, taking into account the molecular status
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluation of miRNA expression based on the 4 molecular groups
- timeFrame
- 1 year
- description
- Evaluate miRNA expression based on the 4 molecular groups recently identified
Secondary outcomes (1)
- measure
- Integration of molecular results with clinico-pathological data
- timeFrame
- 1 year
- description
- Integration of molecular results with clinico-pathological data
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age\>18yo * histological diagnosis of endometrial cancer * tumor resection * patient's informed consent Exclusion Criteria: * patients with other neoplasia within the last 5 years
References
Publications (0)
Data not yet available